12 research outputs found
Thrombopoietin receptor agonist romiplostim in refractory thrombocytopenia as a bridging therapy to the second allogeneic stem cell transplantation
Thrombopoietin (TPO) receptor agonist romiplostim mimic the action of TPO and stimulate the activation, proliferation and maturation of megakaryocytes, resulting in an increase in circulating platelet counts. In this work, we present a patient with a Ph-negative chronic myeloid leukemia (CML) with refractory thrombocytopenia treated with romiplostim as a bridging therapy to the second allogeneic stem cell transplantation (alloSCT). A 56-year old male patient was diagnosed with an atypical Ph-negative CML. One year after the diagnosis he underwent alloSCT from HLA-matched unrelated donor, but had early graft rejection, with severe bleeding diathesis, anemia and thrombocytopenia refractory to transfusion therapy. In addition to daily platelet transfusions (sometimes 2 times per day), he received tranexamic acid and intravenous immunoglobulins. Since the severe thrombocytopenia persisted, romiplostim was introduced as subcutaneous once per week treatment. After two weeks of romiplostim therapy, platelet count increased and the need for platelet transfusions decresed, and he was further followed up in outpatient setting receiving romiplostim as a bridging therapy to his second alloSCT that he received latter. This work describe an unusual use of the TPO receptor agonist as a bridging therapy between two alloSCTs to treat severe refractory thrombocytopenia
Biologic therapy and pregnancy ā a tertiary center experience
BioloÅ”ka se terapija primjenjuje u lijeÄenju upalnih reumatskih bolesti posljednjih desetak godina Äime se znatno unaprijedila kontrola aktivnosti bolesti. Sigurnost primjene bioloÅ”ke terapije u pretkoncepcijskom razdoblju te tijekom trudnoÄe i laktacije veoma je važna pri planiranju lijeÄenja mladih bolesnica. Ni AmeriÄka agencija za hranu i lijekove ni Europska agencija za lijekove do danas nisu nijedan bioloÅ”ki lijek proglasile sigurnim u trudnoÄi. Europska liga protiv reumatizma i Britansko reumatoloÅ”ko druÅ”tvo predložili su smjernice
za lijeÄenje reumatoloÅ”kih bolesnica tijekom trudnoÄe i laktacije, dok AmeriÄko reumatoloÅ”ko druÅ”tvo trenutaÄno izraÄuje smjernice za terapijski pristup u trudnoÄi. S druge strane, objavljeni su mnogi radovi o ishodima trudnoÄa u bolesnica lijeÄenih inhibitorima faktora tumorske nekroze i drugom bioloÅ”kom terapijom, s malim brojem neželjenih ishoda. Cilj je ovog rada bila analiza primjene bioloÅ”ke terapije u bolesnica koje su planirano ili neplanirano zanijele za vrijeme lijeÄenja u naÅ”oj ustanovi te ishoda tih trudnoÄa. NaÅ”i se rezultati ne razlikuju od dosad objavljene literature. Petnaest prikazanih bolesnica primalo je jedan od blokatora tumorske nekroze-Ī±, a jedna bolesnica blokator interleukina- 6 tijekom trudnoÄe ili neposredno prije zaÄeÄa. Samo su dvije bolesnice poÅ”tovale preporuÄeni minimalni period od obustave terapije do zaÄeÄa. Od navedenih 16 bolesnica 3 su imale medicinski indiciran prekid trudnoÄe: jedna zbog teÅ”ke malformacije ploda, a dvije zbog terapije konvencionalnim lijekovima koji modificiraju bolest, a kontraindicirani su u trudnoÄi.Treatment of inflammatory rheumatic diseases and control of disease activity have considerably improved after the introduction of biologic therapy over a decade ago. The safety profile of biologic therapy in the preconception period as well as during pregnancy and lactation is neccessary to consider when planning the treatment of young
female patients. Neither the Food and Drug Administration Agency nor the European Medicines Agency have declared biologic therapy safe during pregnancy. Both the European League Against Rheumatism and the British Society for Rheumatology proposed guidelines for the treatment of female rheumatology patients during pregnancy and lactation, and the American College of Rheumatology is currently developing guidelines for the therapeutic approach during pregnancy. On the other hand, there are numerous publications of pregnancy outcomes in patients treated with biologic therapy, with a small number of adverse effects. We analyzed the modalities of biologic therapy and pregnancy outcomes in patients treated at our Department, during planned and unplanned pregnancies. Our results do not differ from the literature published to date. Among the patients described here, 15 were treated with an inhibitor of tumor necrosis factor-Ī± and one with an IL-6 inhibitor during or just before pregnancy. Only 2 patients stopped biologic therapy in compliance with the guidelines. Of the 16 aforementioned patients, 3 had to undergo medically-induced abortion;
one patient because of a severe fetal malformation and the other two patients because they had bee
Immune thrombocytopenia
Imuna trombocitopenija (ITP) je steÄena, imunoloÅ”ki posredovana bolest odraslih i djece, Äija
je glavna karakteristika, prolazni ili trajni, razliÄiti stupanj trombocitopenije. Broj trombocita
manji od 100 x 109/L uzima se kao graniÄna vrijednost za dijagnozu ITP-a. Dijeli se na
primarnu i sekundarnu. Primarna ITP je ona koja se javlja bez poznatog uzroka, dok je
sekundarna nastala temeljem podležeÄe osnovne bolesti. KliniÄka slika varira od
asimptomatskih formi, preko mukokutanih krvarenja, do moguÄeg životno ugrožavajuÄeg
krvarenja, s intrakranijalnim krvarenjem kao najtežom formom. Dijagnostika primarnog ITP-a
temelji se na iskljuÄivanju drugih, moguÄih uzroka trombocitopenije (poput virusnih bolesti,
imunodeficijencije, autoimunih ili limfoproliferativnih bolesti, primjene antitrombocitnih i
drugih lijekova), jer specifiÄni dijagnostiÄki test ne postoji. Detaljno uzeta anamneza i kliniÄki
pregled prvi je korak u daljnjoj dijagnostici, a kompletna krvna slika i periferni razmaz krvi
trebali bi pokazati samo izoliranu trombocitopeniju, bez drugih patoloŔkih promjena.
Terapijski plan treba individualizirati; osim vrijednosti trombocita i krvareÄih manifestacija,
drugi Äimbenici poput životnog stila, dobi, lijekova i komorbiditeta, pridonose odluci je li
lijeÄenje potrebno. Prva terapijska linija su kortikosteroidi, s ili bez intravenskih
imunoglobulina. U kroniÄnom tipu ITP-a Äesto su nužne druge terapijske linije, poput
splenektomije, agonista trombopoetinskih receptora, rituksimaba, ili drugih imunosupresiva.
Sveukupno gledajuÄi, ITP je bolest koja može varirati od asimptomatskih do teÅ”kih kliniÄkih
slika, od samo limitirajuÄe do kroniÄne bolesti. U evaluaciji i lijeÄenju bolesti, treba se voditi
preporuÄenim smjernicama, ali isto tako prilagoditi terapijski plan, koji Äe najviÅ”e odgovarati
individualnom bolesniku.Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease of adults and
children, whose main characteristic is a transient or persistent thrombocytopenia of a different
degree. A platelet count less than 100 x 109/L is established as the threshold for ITP
diagnosis. It is classified as a primary or secondary form. Primary ITP is the one that occurs
without known cause, while secondary ITP is caused by underlying disease. Clinical
presentation varies from asymptomatic forms, through mucocutaneous bleeding, to life threatening
bleeding, with intracranial bleeding as the most severe form. Diagnosis of primary
ITP is based on the exclusion of other possible causes of thrombocytopenia (such as viral
diseases, immunodeficiency, autoimmune or lymphoproliferative diseases, use of
antithrombotic or other drugs) because a specific diagnostic test does not exist. Carefully
taken patient's history and physical examination are the first steps in the further diagnostic
process. Peripheral blood count and peripheral blood smear should show isolated
thrombocytopenia without other pathological changes. The therapeutic plan should be
individualized; besides platelet count and bleeding manifestations, other factors like lifestyle,
age, medication and comorbidities, contribute to decision whether the treatment is needed or
not. The first-line treatment are corticosteroids, with or without intravenous immunoglobulins.
The chronic ITP often requires other treatment lines, such as splenectomy, thrombopoietic
receptor agonists, rituximab, or other immunosuppressants. Overall, ITP is a disease that may
vary from asymptomatic to severe clinical forms and from the self-limited to the chronic
illness. In evaluation and management of ITP, the recommended guidelines should be
followed, but also adapted to the treatment plan that will suit the individual patient the best
Immune thrombocytopenia
Imuna trombocitopenija (ITP) je steÄena, imunoloÅ”ki posredovana bolest odraslih i djece, Äija
je glavna karakteristika, prolazni ili trajni, razliÄiti stupanj trombocitopenije. Broj trombocita
manji od 100 x 109/L uzima se kao graniÄna vrijednost za dijagnozu ITP-a. Dijeli se na
primarnu i sekundarnu. Primarna ITP je ona koja se javlja bez poznatog uzroka, dok je
sekundarna nastala temeljem podležeÄe osnovne bolesti. KliniÄka slika varira od
asimptomatskih formi, preko mukokutanih krvarenja, do moguÄeg životno ugrožavajuÄeg
krvarenja, s intrakranijalnim krvarenjem kao najtežom formom. Dijagnostika primarnog ITP-a
temelji se na iskljuÄivanju drugih, moguÄih uzroka trombocitopenije (poput virusnih bolesti,
imunodeficijencije, autoimunih ili limfoproliferativnih bolesti, primjene antitrombocitnih i
drugih lijekova), jer specifiÄni dijagnostiÄki test ne postoji. Detaljno uzeta anamneza i kliniÄki
pregled prvi je korak u daljnjoj dijagnostici, a kompletna krvna slika i periferni razmaz krvi
trebali bi pokazati samo izoliranu trombocitopeniju, bez drugih patoloŔkih promjena.
Terapijski plan treba individualizirati; osim vrijednosti trombocita i krvareÄih manifestacija,
drugi Äimbenici poput životnog stila, dobi, lijekova i komorbiditeta, pridonose odluci je li
lijeÄenje potrebno. Prva terapijska linija su kortikosteroidi, s ili bez intravenskih
imunoglobulina. U kroniÄnom tipu ITP-a Äesto su nužne druge terapijske linije, poput
splenektomije, agonista trombopoetinskih receptora, rituksimaba, ili drugih imunosupresiva.
Sveukupno gledajuÄi, ITP je bolest koja može varirati od asimptomatskih do teÅ”kih kliniÄkih
slika, od samo limitirajuÄe do kroniÄne bolesti. U evaluaciji i lijeÄenju bolesti, treba se voditi
preporuÄenim smjernicama, ali isto tako prilagoditi terapijski plan, koji Äe najviÅ”e odgovarati
individualnom bolesniku.Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease of adults and
children, whose main characteristic is a transient or persistent thrombocytopenia of a different
degree. A platelet count less than 100 x 109/L is established as the threshold for ITP
diagnosis. It is classified as a primary or secondary form. Primary ITP is the one that occurs
without known cause, while secondary ITP is caused by underlying disease. Clinical
presentation varies from asymptomatic forms, through mucocutaneous bleeding, to life threatening
bleeding, with intracranial bleeding as the most severe form. Diagnosis of primary
ITP is based on the exclusion of other possible causes of thrombocytopenia (such as viral
diseases, immunodeficiency, autoimmune or lymphoproliferative diseases, use of
antithrombotic or other drugs) because a specific diagnostic test does not exist. Carefully
taken patient's history and physical examination are the first steps in the further diagnostic
process. Peripheral blood count and peripheral blood smear should show isolated
thrombocytopenia without other pathological changes. The therapeutic plan should be
individualized; besides platelet count and bleeding manifestations, other factors like lifestyle,
age, medication and comorbidities, contribute to decision whether the treatment is needed or
not. The first-line treatment are corticosteroids, with or without intravenous immunoglobulins.
The chronic ITP often requires other treatment lines, such as splenectomy, thrombopoietic
receptor agonists, rituximab, or other immunosuppressants. Overall, ITP is a disease that may
vary from asymptomatic to severe clinical forms and from the self-limited to the chronic
illness. In evaluation and management of ITP, the recommended guidelines should be
followed, but also adapted to the treatment plan that will suit the individual patient the best
Immune thrombocytopenia
Imuna trombocitopenija (ITP) je steÄena, imunoloÅ”ki posredovana bolest odraslih i djece, Äija
je glavna karakteristika, prolazni ili trajni, razliÄiti stupanj trombocitopenije. Broj trombocita
manji od 100 x 109/L uzima se kao graniÄna vrijednost za dijagnozu ITP-a. Dijeli se na
primarnu i sekundarnu. Primarna ITP je ona koja se javlja bez poznatog uzroka, dok je
sekundarna nastala temeljem podležeÄe osnovne bolesti. KliniÄka slika varira od
asimptomatskih formi, preko mukokutanih krvarenja, do moguÄeg životno ugrožavajuÄeg
krvarenja, s intrakranijalnim krvarenjem kao najtežom formom. Dijagnostika primarnog ITP-a
temelji se na iskljuÄivanju drugih, moguÄih uzroka trombocitopenije (poput virusnih bolesti,
imunodeficijencije, autoimunih ili limfoproliferativnih bolesti, primjene antitrombocitnih i
drugih lijekova), jer specifiÄni dijagnostiÄki test ne postoji. Detaljno uzeta anamneza i kliniÄki
pregled prvi je korak u daljnjoj dijagnostici, a kompletna krvna slika i periferni razmaz krvi
trebali bi pokazati samo izoliranu trombocitopeniju, bez drugih patoloŔkih promjena.
Terapijski plan treba individualizirati; osim vrijednosti trombocita i krvareÄih manifestacija,
drugi Äimbenici poput životnog stila, dobi, lijekova i komorbiditeta, pridonose odluci je li
lijeÄenje potrebno. Prva terapijska linija su kortikosteroidi, s ili bez intravenskih
imunoglobulina. U kroniÄnom tipu ITP-a Äesto su nužne druge terapijske linije, poput
splenektomije, agonista trombopoetinskih receptora, rituksimaba, ili drugih imunosupresiva.
Sveukupno gledajuÄi, ITP je bolest koja može varirati od asimptomatskih do teÅ”kih kliniÄkih
slika, od samo limitirajuÄe do kroniÄne bolesti. U evaluaciji i lijeÄenju bolesti, treba se voditi
preporuÄenim smjernicama, ali isto tako prilagoditi terapijski plan, koji Äe najviÅ”e odgovarati
individualnom bolesniku.Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease of adults and
children, whose main characteristic is a transient or persistent thrombocytopenia of a different
degree. A platelet count less than 100 x 109/L is established as the threshold for ITP
diagnosis. It is classified as a primary or secondary form. Primary ITP is the one that occurs
without known cause, while secondary ITP is caused by underlying disease. Clinical
presentation varies from asymptomatic forms, through mucocutaneous bleeding, to life threatening
bleeding, with intracranial bleeding as the most severe form. Diagnosis of primary
ITP is based on the exclusion of other possible causes of thrombocytopenia (such as viral
diseases, immunodeficiency, autoimmune or lymphoproliferative diseases, use of
antithrombotic or other drugs) because a specific diagnostic test does not exist. Carefully
taken patient's history and physical examination are the first steps in the further diagnostic
process. Peripheral blood count and peripheral blood smear should show isolated
thrombocytopenia without other pathological changes. The therapeutic plan should be
individualized; besides platelet count and bleeding manifestations, other factors like lifestyle,
age, medication and comorbidities, contribute to decision whether the treatment is needed or
not. The first-line treatment are corticosteroids, with or without intravenous immunoglobulins.
The chronic ITP often requires other treatment lines, such as splenectomy, thrombopoietic
receptor agonists, rituximab, or other immunosuppressants. Overall, ITP is a disease that may
vary from asymptomatic to severe clinical forms and from the self-limited to the chronic
illness. In evaluation and management of ITP, the recommended guidelines should be
followed, but also adapted to the treatment plan that will suit the individual patient the best